Clinical Trial Update: Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Lucentis (ranibizumab) as adjuvant therapy with TTT-ICG for choroidal melanoma has completed and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Melanoma

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: New England Retina Associates | Conditions: Choroidal Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2017-04-12